Protocollo per il campionamento di fitoplancton in ambiente lacustre

No abstract availabl

Protocollo di campionamento di macrofite acquatiche in ambiente lacustre

No abstract availableIl presente rapporto descrive la procedura per effettuare il corretto campionamento delle macrofite in ambiente lacustre, allo scopo di impiegare i dati ottenuti per una valutazione di qualit? ecologica dei laghi, secondo quanto previsto dalla Direttiva Comunitaria 2000/60

IMMU-01. TEM-GBM: AN OPEN-LABEL, PHASE I/IIA DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND EFFICACY OF GENETICALLY MODIFIED TIE-2 EXPRESSING MONOCYTES TO DELIVER IFN-A WITHIN GLIOBLASTOMA TUMOR MICROENVIRONMENT

Abstract Temferon is a macrophage-based treatment relying on ex-vivo transduction of autologous HSPCs to express immune-payloads within the TME. Temferon targets the immune-modulatory molecule IFN-a, to a subset of tumor infiltrating macrophages known as Tie-2 expressing macrophages (TEMs) due to the Tie2 promoter and a post-transcriptional regulation layer represented by miRNA-126 target sequences. As of 31st May 2021, 15-patients received Temferon (D+0) with follow-up of 3 – 693 days. After conditioning neutrophil and platelet engraftment occurred at D+13 and D+13.5, respectively. Temferon-derived differentiated cells, as determined be the number of vector copy per genome, were found within 14 days post treatment and persisted albeit at lower levels up to 18-months. Very low concentrations of IFN-a in the plasma (8.7 pg/ml-D+30) and in the CSF (1.6 pg/ml-D+30) were detected, suggesting tight regulation of transgene expression. Five-deaths occurred at D+322, +340, +402, +478 and +646 due to PD, and one at D+60 due to complications following the conditioning regimen. Eight-patients had progressive disease (range: D-11 to +239) as expected for this tumor type. SAEs include GGT elevation (possibly related to Temferon) and infections, venous thromboembolism, brain abscess, hemiparesis, seizures, anemia and general physical condition deterioration, compatible with ASCT, concomitant medications and PD. Four-patients underwent 2ndsurgery. Recurrent tumors had gene-marked cells and increased expression of ISGs compared to first surgery, indicative of local IFNa release by TEMs. In one patient, a stable lesion had a higher proportion of T cells and TEMs within the myeloid infiltrate and an increased ISGs than in the progressing lesion, detected in the same patient. Tumor-associated clones expanded in the periphery. TME characterization by scRNA and TCR-sequencing is ongoing. To date, Temferon is well tolerated, with no DLTs identified. The results provide initial evidence of Temferon potential to activate the immune system of GBM patients, as predicted by preclinical studies

Decision support tools for measuring and controlling After-Sales service performance

Companies have progressively realised that complementing industrial goods with the provision of value added services can be an important lever to prosper on those markets affected by weak demand, hard competition and decreasing margins. Among the different forms of service provisions, After-Sales services have acquired a strategic role as a source of revenues and competitive advantage. This transition from products to services calls for the creation of expertise, structures and processes new to the product manufacturer. Companies need to mature the capability to design and deliver services rather than products and a fundamental requirement lies in designing specific and appropriate decision support tools to help companies in monitoring their current and future results and the critical trends of the beneath processes. Goal of this paper is to provide a procedure which allows to develop two decision support tools. A case study is proposed as a means to apply and validate the procedure

Towards a reference model for After-Sales service processes

In the last years, given the high market pressure and the increased competition in several industries, the search for new business opportunity is focusing on service activities. After-Sales (AS) service has become increasingly important as a source of differentiation and market share for manufacturers and resellers, as well as a strategic driver for customer’s retention. These changes often call for a new conceptual definition of the product-service bundle marketed to the final customer and for a thorough revision of the logistical and organizational configuration of the whole service chain. It comes out the necessity to design appropriate processes and to have a general and shared definition of their structure. Aim of the paper is to suggest a model which provides a common configuration of the assistance processes according to a framework that links the different typologies of assistance with the product service strategies offered by companies. Some case studies have been considered in order to validate the proposed framework and the model